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Background:  Transcatheter balloon aortic valvuloplasty (BAVP) results in short-term relief of gradient in the majority of neonates with critical 
aortic valve (AV) stenosis . However, little is known about its subacute efficacy and patterns of reintervention.
Methods:  the data from 11 Cardiac Pediatric Institutions on neonates (aged < 30 days) with critical AV stenosis who underwent to BAVP since its 
introduction in each Institution (1985-1988) has been retrospectively reviewed.
Results:  Study population: 207 neonates, mean age at BAVP 8,1 ± 8 days, 115/207 (60%) were younger than 1 week. Mean weight 3.2 (r 1.4-5) 
Kg. 105/207 (56%) Pts had BAVP during prostaglandin E1 infusion. 13 Pts (6%) had a monocuspid AV, 118 (57%) a bicuspid AV and 33 (16%) a 
tricuspid AV; the anatomy of the AV was undefined in 42 Pts (21%). Mean trans-valvular peak gradient decreased from 68.33 ± 34 to 27.4 ± 16 
mmHg ( p < 0.001); 26/207 (13%) Pts developed more than moderate aortic valve regurgitation. Overall mortality was 20.3% (42/207). One-month 
and 1-year mortality were respectively 11% (22/207) and 17% (36/207), thus, 85% of death occurred during the first year. Factors associated with 
mortality were: age < 1 week at BAVP (p = 0.0009), infusion of prostaglandin E1 (p=0.003), association with other left heart obstructive lesions ( p = 
0.0012), mainly, mitral valve abnormalities (p= 0.0009). No correlation was found between AV anatomy and outcome. Mean follow-up was 5,8 (±4,8 
) years. Survival after 10 yrs was 79% (95% CI 69-87). Five and 10 years survival free from aortic valve surgery or repeated BAVP were respectively 
65% (95% CI 58 to 73) and 58 % (95% CI 50 to 70).
Conclusions:  1) this study is the largest series of treatment of neonates with critical AVS; 2) our result are comparable to those reported in the 
literature and confirms the efficacy of BAVP as initial palliation for neonates with CAVS; 3) whole mortality is 20%, 85% of death occurs during the 
first year of life; 4) mortality results associated with a) need of BAVP during the first week of life b) BAVP during infusion of prostaglandins E1; c) 
associated left heart lesions, mainly, mitral valve abnormalities; 5) ten years survival free from AV surgery or repeated BAVP is 58%.
